S. Karger AG

SHERPA: Unknown

People

  1. Bodei
    Bodei
  2. Drilon
    Drilon
  3. Motzer
    Motzer
  4. Abou-Alfa
    Abou-Alfa
  5. Chaganti
    Chaganti
  6. Lin
    Lin
  7. Tang
    Tang
  8. Clarkson
    Clarkson
  9. Janjigian
    Janjigian
  10. Marghoob
    Marghoob

Groups

  1. Department of Medicine (279)
  2. Solid Tumor Oncology Division (160)
  3. Hematologic Malignancies, Division of (107)
  4. Center for Hematologic Malignancies (103)
  5. Survivorship Research (59)
  6. Gastrointestinal Oncology Service (57)
  7. Sloan Kettering Institute Postdocs (55)
  8. Surgery (54)
  9. Sloan Kettering Institute Faculty (47)
  10. Thoracic Oncology (45)
Search Within
Formats
  1. Meeting Abstract (332)
  2. Journal Article (254)
  3. Book Section (20)
  4. Review (15)
  5. Conference Paper (10)
  6. Book Whole (1)
  7. Editorial (1)
Groups
  1. Department of Medicine (279)
  2. Solid Tumor Oncology Division (160)
  3. Hematologic Malignancies, Division of (107)
  4. Center for Hematologic Malignancies (103)
  5. Survivorship Research (59)
  6. Gastrointestinal Oncology Service (57)

More Groups

People
  1. Lisa Bodei (32)
  2. Alexander Drilon (23)
  3. Robert Motzer (23)
  4. Ghassan Abou-Alfa (18)
  5. Steven Hajdu (18)
  6. Oscar Lin (16)

More People

Years
  1. 2025 (3)
  2. 2024 (21)
  3. 2023 (37)
  4. 2022 (42)
  5. 2021 (31)
  6. 2020 (51)

More Years

Publications
  1. Oncology Research and Treatment (226)
  2. Cytogenetics and Cell Genetics (61)
  3. Acta Cytologica (58)
  4. Neuroendocrinology (51)
  5. Acta Haematologica (32)
  6. Onkologie (19)

More Publications

Results (633)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Spotlight: Phase 3 study of Zolbetuximab+mFOLFOX6 versus placebo+mFOLFOX6 in first-line claudin18.2(+)/HER2(-) advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
    Meeting Abstract

    Lordick, F.; Shitara, K.; Al-Batran, S. E.; Bang, Y. J.; Catenacci, D.; Enzinger, P.; Ilson, D.; Kim, S.; Shah, M. A.; Van Cutsem, E.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in ≥ fourth-line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS
    Meeting Abstract

    Reichardt, P.; Heinrich, M.; George, S.; Zalcberg, J. R.; Bauer, S.; Gelderblom, H.; Schöffski, P.; Serrano, C.; Jones, R. L.; Attia, S.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Intra-patient comparison from larotrectinib clinical trials in TRK fusion cancer - An expanded dataset
    Meeting Abstract

    Leyvraz, S.; Italiano, A.; Hong, D. S.; Briggs, A.; Garcia-Foncillas, J.; Lassen, U. N.; Vassal, G.; Kummar, S.; van Tilburg, C. M.; Keating, K.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227
    Meeting Abstract

    Schumann, C.; Paz-Ares, L.; Ciuleanu, T. E.; Lee, J. S.; Urban, L.; Caro, R. B.; Park, K.; Sakai, H.; Ohe, Y.; Nishio, M.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: Updated results of a phase Ib/II randomized study and preliminary results of a Single-arm extension
    Meeting Abstract

    Sehn, L. H.; Hess, G.; Hertzberg, M.; Opat, S.; Herrera, A. F.; Assouline, S.; Flowers, C. R.; Kim, T. M.; McMillan, A.; Ozcan, M.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • ECHELON-2, (NCT01777152), 5-year results of a randomised, double-blind, phase 3 study of frontline brentuximab vedotin plus CHP vs CHOP in patients with CD30-positive peripheral T-cell lyphoma
    Meeting Abstract

    Trümper, L.; O'Connor, O. A.; Pro, B.; Illidge, T.; Advani, R.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; Rossi, G.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • CPI-0610, a bromodomain and extraterminal domain (BET) protein inhibitor, in combination with ruxolitinib, in JAK-inhibitor-naïve myelofibrosis patients: Update of MANIFEST phase 2 study
    Meeting Abstract

    Platzbecker, U.; Mascarenhas, J.; Harrison, C.; Patriarca, A.; Devos, T.; Palandri, F.; Rampal, R.; Vannucchi, A.; Mead, A.; Kremyanskaya, M.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Tepotinib in patients (pts) with MET exon 14 (METex14) skipping NSCLC: Efficacy results from all pts enrolled in VISION Cohort A
    Meeting Abstract

    Thomas, M.; Reinmuth, N.; Wermke, M.; Griesinger, F.; Overbeck, T.; Alt, J.; Henschke, S.; Wehler, T.; Ochsenreither, S.; Garassino, M. C.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • CHRONOS-3: Randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL)
    Meeting Abstract

    Dreyling, M.; Matasar, M. J.; Capra, M.; Özcan, M.; Lv, F.; Li, W.; Yanez, E.; Sapunarova, K.; Lin, T.; Jin, J.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • 5-year survival outcomes with durvalumab after chemoradiotherapy in unresectable Stage III NSCLC - An update from the PACIFIC trial
    Meeting Abstract

    de Wit, M.; Spigel, D. R.; Faivre-Finn, C.; Gray, J. E.; Vicente, D.; Planchard, D.; Paz-Ares, L.; Vansteenkiste, J. F.; Garassino, M. C.; Hui, R.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save